ABSTRACT
Objective To prepare lappaconitine hydrobromide push-pull osmotic pump controlled release tablets and screen for the optimal formulation. Methods The percent of cumulative release was used as the evaluation index for the drug release profile in vitro. The effects of PEO N750, PEO WSR303, and plasticizer amounts and coating weight gain on the releasing behavior were investigated through single-factor method. Based on single-factor study on the compositions, the optimal formulation for lappaconitine hydrobromide push-pull osmotic pump controlled release tablet was selected via orthogonal design. The in vitro release of the optimized formulation was also fitted to different models. Results The results of orthogonal design indicated that coating weight gain had a significant effect on the drug release in vitro —<0. 05). The optimal formula was as follows; lappaconitine hydrobromide 20 mg, PEO N750 160 mg, NaCl 30 mg in drug layer; PEO WSR303 75 mg, NaCl 20 mg in the push layer; and plasticizer PEG 4000 was 10% and weight gain was 5% in the coating composition The release rate of the tablets with optimized formulation was constant within 12 h, and the cumulative release could reach 95. 02 %. Conclusion The current method to prepare lappaconitine hydrobromide push-pull osmotic pump controlled release tablets is stable, and the in vitro drug release has an excellent zero-release profile within 12 h (r=0. 992 1), which meets the standard for controlled release.
ABSTRACT
OBJECTIVES : Long acting injectable antipsychotic medication have the ability to sustain the drug effect for a long duration, thus enabling advances in the management of those psychiatric patients who have poor compliance or who have difficulty getting the oral form of their antipsychotic medications. Despite their benefits, previous studies have reported that depot antipsychotics have a much lower prescription ratein the treatment of schizophrenia or schizoaffective disorder. Psychiatrist's attitude toward depot antipsychotics clearly has an influence on the decision-making process regarding the selection of medications. Until now, there has been no data with respect to psychiatrists' attitudes regarding long-acting injectable antipsychotics in Korea. This study examined these attitudes toward antipsychotic depot medications as well as the factors which could contribute to their choice of depots. METHODS : We questioned 347 psychiatrists, who had been attending a conference, about their attitudes toward depot antipsychotic treatment. RESULTS : The most important factor causing reluctance with respect to prescribing depot treatment (for both classes of antipsychotics) was a presumed sufficient level of compliance with available oral antipsychotic treatments. In addition, typical depots are not considered to be an appropriate treatment option for first-episode patients, and as a result, they are used sparingly. Lastly, atypical longacting injectable drugs are avoided due to their strict criteria of insurance and high treatment costs. CONCLUSION : Aversions to prescribe depot treatment are frequent among psychiatrists and appear to be unrelated to the antipsychotic class. The stated reasons for not choosing depots are generally not supported by the current literature. Further research is required to clarify the advantages using depot treatments.
Subject(s)
Humans , Antipsychotic Agents , Attitude of Health Personnel , Compliance , Delayed-Action Preparations , Health Care Costs , Insurance , Korea , Prescriptions , Psychiatry , Psychotic Disorders , SchizophreniaABSTRACT
Objeract:To evaluate the effects of controlled release tinidazole(TNZ) membrane in the treatment of adult periodontitis. Methods:Adult periodontitis was treated with TNZ membrane in 15 cases (25 teeth),with Metronidazole(MNZ) in 15 cases (24 teeth) and with vehicle membrane in 15 cases (25 teeth).The effects were evaluated by clinical observation,biochemical examination and becteria test. Results: TNZ membrane more significantly inhibited bacteria (P